Phase III Clinical Study of Efficacy and Safety of Vaccae™ to Prevent Tuberculosis

NCT ID: NCT01979900

Last Updated: 2018-06-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 10000 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-10-31
• Study Completion Date: 2017-11-26

Brief Summary

Mycobacterium Vaccae for Injection (Trade Name "Vaccae") is a kind of bio-products developed by Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd.,and got "The New Drug Certificate "in 1999. Vaccae has been approved for adjuvant therapy of tuberculosis(TB), and is also the only recommended drug in TB immunotherapy by WHO. It was approved for production and sale by Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd. in 2001, and got favourable comment in therapy of tuberculosis.

The purpose of this study is to add new indications for Vaccae, mainly to prevent Tuberculosis for high risk groups of Tuberculosis Infection . In December 2012, China Food and Drug Administration approved of the plan "Phase III Clinical Study of Efficacy and Safety of Mycobacterium Vaccae to Prevent Tuberculosis in high risk groups of Tuberculosis Infection". In the test, 10,000 cases whose skin tests of PPD are strongly positive are enrolled. Using random, double-blind, and placebo-controlled methods, the study is carried out to evaluate the efficacy and safety of Vaccae in preventing Tuberculosis. Meanwhile, in this test, TB incidence and degree of pathological changes of experimental group are lower than that of control group, and no drug-related SAEs are reported in treatment groups.

Detailed Description

The Main Purpose of the Study:

• Evaluation of efficacy of Vaccae to prevent Tuberculosis in high risk groups of Tuberculosis Infection.

The Secondary Purpose of the Study:

• Evaluation of Lesion Degree ( Bacteriology Indicators, Cavity) of patients and its relationship with Skin Test results of TB-PPD after Injection of Vaccae into the high risk groups.
• Evaluation of Changes in Humoral Immunity and Cellular Immunologic Response Before and After Injection of Vaccae

Test Hypothesis:

In the test, TB incidence and degree of pathological changes of experimental group are lower than that of control group, and no drug-related SAEs are reported in treatment groups

Blinding and Random:

Using random, double-blind, and placebo-controlled methods, evaluation of the efficacy and safety of Vaccae.

Using block randomization method, a random sequence was generated by the statistics personnel in Fourth Military Medical University Clinical Evaluation Center using SAS9.1.3 statistical software

The Unblinding includes the first time of Unblinding and the second time of Unblinding. The first time of Unblinding only distinguish groups , and the second time of Unblinding will uncover the final Blind Codes.

The Blind Codes of the design produce at one time, and unblinding will be carried out respectively at the first year and the second year after the beginning of the experiment.

Conditions

Tuberculosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: DOUBLE

Study Groups

Vaccae

Experiment group:One vial of Vaccae diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally.

Group Type: EXPERIMENTAL

Vaccae

Intervention Type: DRUG

One vial of Vaccae diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally.

Placebo

Placebo group:One vial of placebo diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: DRUG

One vial of placebo diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well，once every 2 weeks, 6 times totally.

Interventions

Vaccae

One vial of Vaccae diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally.

Intervention Type: DRUG

placebo

One vial of placebo diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well，once every 2 weeks, 6 times totally.

Intervention Type: DRUG

Other Intervention Names

Mycobacterium vaccae for Injection; Vaccae Lyophilized stabilizers

Eligibility Criteria

Inclusion Criteria

• Aged from 15 to 65 years old, all genders.
• Skin test of Tuberculin Pure Protein Derivative (TB-PPD) is strongly positive ( the average diameter of PPD skin test induration is greater than or equal to 15mm,and（or）local blisters, necrosis).
• Agreed to participate in the test and sign the informed consent.
• Subjects agreed to participate in the experiments and voluntarily signed the informed consent. (guardians of 15-17- year-old subjects should agree, meanwhile).
• The subjects should comply with the requirements of the clinical trial protocol and be Followed.
• Have not participated in any other clinical trial for nearly three months.
• Women of childbearing age from 15 to 49 years should agree with urine pregnancy tests and take effective birth control measures in two years after the medication.
• Axillary temperature is normal.

Exclusion Criteria

• Suffering from any other serious disease, e.g. during cancer treatment, autoimmune disease, progressive atherosclerosis, diabetes accompanied with complications, chronic obstructive pulmonary disease (COPD) needing oxygen therapy, acute or progressive liver or kidney disease, congestive heart failure, etc.
• Known allergy to experiment drugs
• People with history of specific diagnosis of TB, extrapulmonary tuberculosis or have been cured
• People have history of allergy, convulsions, epilepsy, cerebropathy, neurological symptoms and signs
• Patients who have impaired or abnormal immune function, e.g. patients treated with immunosuppressor or immunopotentiator, received immunoglobulin preparation or blood products or plasma extraction outside the gastrointestinal tract in 3 months, human immunodeficiency virus or related diseases
• Oral corticosteroids
• Patients who have been using oral corticosteroids for more than 1 week, or hormone medication in vitro for a long time
• Acute febrile illness and infection
• Pregnant or lactating women, or women who have birth plan in following 2 years
• Any other cases that may influence the test evaluation

• Subjects whose compliance is poor, and can not take medicine on time or according to the amount
• Patients who are using medicine and food that can influence the result
• Pregnant subjects during the test
• Patients who are reluctant to continue and require exit

• Minimum Eligible Age: 15 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Guangxi Center for Disease Control and Prevention

OTHER_GOV

Sponsor Role: collaborator

Liuzhou Center for Disease Control and Prevention,China

UNKNOWN

Sponsor Role: collaborator

Rongshui County Disease Control and Prevention,China

UNKNOWN

Sponsor Role: collaborator

Liucheng County Disease Control and Prevention,China

UNKNOWN

Sponsor Role: collaborator

Jin Chengjiang Center for Disease Control and Prevention,China

UNKNOWN

Sponsor Role: collaborator

National Institutes for Food and Drug Control, China

OTHER

Sponsor Role: collaborator

Air Force Military Medical University, China

OTHER

Sponsor Role: collaborator

Simoon Record Pharma Information Consulting Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Guoai Si, Director

Role: PRINCIPAL_INVESTIGATOR

Jin Chengjiang Center for Diseases Control and Prevention, Hechi, Guangxi

Mingqiang Li, Director

Role: PRINCIPAL_INVESTIGATOR

Jin Chengjiang Center for Diseases Control and Prevention, Liuzhou, Guangxi

Keshua Meng, Director

Role: PRINCIPAL_INVESTIGATOR

Rongshui County Diseases Control and Prevention, Liuzhou, Guangxi

Debiao Qiao, Director

Role: PRINCIPAL_INVESTIGATOR

Liucheng County Diseases Control and Prevention, Liuzhou, Guangxi

Locations

Jin Chengjiang Center for Diseases Control and Prevention, Hechi, Guangxi

Hechi, Guangxi, China

Liucheng County Diseases Control and Prevention, Liuzhou, Guangxi

Liuzhou, Guangxi, China

Liuzhou Center for Diseases Control and Prevention, Liuzhou, Guangxi

Liuzhou, Guangxi, China

Rongshui County Diseases Control and Prevention, Liuzhou, Guangxi

Liuzhou, Guangxi, China

Countries

China

References

Moran-Mendoza O, Marion SA, Elwood K, Patrick DM, FitzGerald JM. Tuberculin skin test size and risk of tuberculosis development: a large population-based study in contacts. Int J Tuberc Lung Dis. 2007 Sep;11(9):1014-20.

Reference Type: BACKGROUND

PMID: 17705981 (View on PubMed)

Related Links

https://wbca.cde.org.cn/wbca/clinmain.do?method=edit&ckmIdCode=2A2F055FEFF749918149A70D4830FE3C

Center for drug evaluation, CFDA ,China

Other Identifiers

LTao

Identifier Type: -

Identifier Source: org_study_id